Renaissance Capital logo

TSRX News

Trius Therapeutics slashes IPO price to $5, offers more shares

Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, raised $50 million by offering 10 million shares at $5 after originally planning to sell 6 million shares at a range of $12-$14. Trius Therapeutics plans to list...read more

Trius Therapeutics decreases proposed IPO deal size

Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, lowered the proposed deal size for its upcoming IPO on Monday. The San Diego, CA-based company now plans to raise $50 million by offering 10 million shares at a...read more

Biotech Trius Therapeutics back on IPO calendar for week of July 26

Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, kicked off a new IPO roadshow this week after temporarily postponing its IPO in March to adjust the Phase 3 protocol for its lead drug. The San Diego, CA-based biotech,...read more

Trius Therapeutics delays $78 million IPO to conform protocol for Phase 3 trial

Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, announced that it is temporarily postponing its IPO due to plans to conform Phase 3 protocol for the drug (torezolid phosphate) to accomodate new draft guidance recently...read more